current
approv
specif
antivir
agent
novel
coronaviru
diseas
studi
ten
sever
patient
confirm
realtim
viral
rna
test
enrol
prospect
one
dose
ml
convalesc
plasma
cp
deriv
recent
recov
donor
neutral
antibodi
titer
transfus
patient
addit
maxim
support
care
antivir
agent
primari
endpoint
safeti
cp
transfus
second
endpoint
improv
clinic
symptom
laboratori
paramet
within
day
cp
transfus
median
time
onset
ill
cp
transfus
day
cp
transfus
level
neutral
antibodi
increas
rapidli
five
case
four
case
maintain
high
level
clinic
symptom
significantli
improv
along
increas
oxyhemoglobin
satur
within
day
sever
paramet
tend
improv
compar
pretransfus
includ
increas
lymphocyt
count
l
vs
l
decreas
creactiv
protein
mgl
vs
mgl
radiolog
examin
show
vari
degre
absorpt
lung
lesionswithin
day
viral
load
undetect
transfus
seven
patient
previou
viremia
sever
advers
effect
observ
studi
show
cp
therapi
welltoler
could
potenti
improv
clinic
outcom
neutral
viremia
sever
case
optim
dose
time
point
well
clinic
benefit
cp
therapi
need
investig
larger
wellcontrol
trial
current
big
threat
global
health
howev
specif
antivir
agent
avail
treatment
work
explor
feasibl
convalesc
plasma
cp
transfus
rescu
sever
patient
result
sever
adult
case
show
one
dose
ml
cp
welltoler
could
significantli
increas
maintain
neutral
antibodi
high
level
lead
disappear
viremia
day
meanwhil
clinic
symptom
paraclin
criteria
rapidli
improv
within
day
radiolog
examin
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
show
vari
degre
absorpt
lung
lesion
within
day
result
indic
cp
serv
promis
rescu
option
sever
random
trial
warrant
sinc
decemb
pneumonia
associ
sever
acut
respiratori
syndrom
coronaviru
name
novel
coronaviru
diseas
world
health
organ
emerg
wuhan
china
epidem
spread
rapidli
worldwidewithin
three
month
character
pandem
march
march
total
case
report
china
meanwhil
total
confirm
case
death
report
countri
regionscurr
approv
specif
antivir
agent
target
novel
viru
drug
still
investig
includ
remdesivir
lopinavirritonavir
although
remdesivirwa
report
possess
potenti
antivir
effectin
one
patient
us
random
control
trial
drug
ongo
determin
safeti
efficaci
moreov
corticosteroid
treatment
lung
injuri
remain
controversi
due
delay
clearanc
viral
infect
complic
sinc
effect
vaccin
specif
antivir
medicin
unavail
urgent
need
look
altern
strategi
treatment
especi
amongsever
patient
convalesc
plasma
cp
therapi
classic
adaptiveimmunotherapi
appli
prevent
treatment
mani
infecti
diseas
one
centuri
past
two
decad
cp
therapi
success
use
treatment
sar
mer
pandem
satisfactori
efficaci
safeti
metaanalysi
studi
sar
coronaviru
infect
sever
influenza
show
statist
signific
reduct
pool
odd
mortal
follow
cp
therapi
compar
placebo
therapi
odd
ratio
confid
interv
howev
cp
therapi
unabl
significantli
improv
surviv
ebola
viru
diseas
probabl
due
absenc
data
neutral
antibodytitrationfor
stratifi
analysi
sinc
virolog
clinic
characterist
share
similar
among
sar
mer
cp
therapi
might
promis
treatment
option
rescu
patient
recov
high
neutral
antibodi
titermay
bea
valuabl
donor
sourc
cp
nevertheless
potenti
clinic
benefit
risk
convalesc
blood
product
remain
uncertain
henc
perform
pilot
studi
three
particip
hospit
explor
feasibl
cptreatment
sever
patient
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
neutral
activ
evalu
classic
plaqu
reduct
test
use
recent
isol
viral
strain
among
first
batch
cp
sampl
recov
patient
show
high
antibodi
titer
least
wherea
one
antibodi
titer
result
laid
basi
pilot
clinic
trial
use
cp
sever
patient
januari
februari
ten
sever
patient
six
male
four
femal
enrol
receiv
cp
transfus
median
age
year
iqr
year
tabl
none
patient
direct
exposur
huanan
seafood
wholesal
market
median
time
onset
symptom
hospit
admiss
cp
transfus
day
iqr
day
day
day
respect
three
patient
affect
cluster
infect
common
symptom
diseas
onset
fever
seven
ten
patient
cough
eight
case
short
breath
eight
case
less
common
symptom
includ
sputum
product
five
case
chest
pain
two
case
diarrhea
two
case
nausea
vomit
two
case
headach
one
case
sore
throat
one
case
four
patient
underli
chronic
diseas
includ
cardiovascular
andor
cerebrovascular
diseas
essenti
hypertens
nine
patient
receiv
arbidolmonotherapi
combin
therapi
remdesivir
one
case
includ
current
clinic
trial
ribavirin
peramivir
one
patient
receiv
ribavirin
monotherapi
tabl
antibacteri
antifung
treatment
use
patient
coinfect
six
patient
receiv
intravenousmethylprednisolon
mg
everi
hr
computerassist
tomographi
ct
patient
present
bilater
groundglass
opac
andor
pulmonari
parenchym
consolid
predominantli
subpleur
bronchovascular
bundl
distribut
lung
seven
patient
multipl
lobe
involv
four
patient
interlobular
septal
thicken
improv
clinic
symptomsal
symptom
inth
patient
especi
fever
cough
short
breath
chest
pain
disappear
larg
improv
within
day
upon
cp
transfus
prior
tocp
treatment
three
patient
receiv
mechan
ventil
three
receiv
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
highflow
nasal
cannula
oxygen
two
receiv
convent
lowflow
nasal
cannula
oxygen
treatmentwith
cp
two
patient
wean
mechan
ventil
highflow
nasal
cannula
one
patient
discontinu
high
flow
nasal
cannula
besid
one
patient
treat
convent
nasal
cannula
oxygen
continu
oxygen
shift
intermitt
one
tabl
tabl
total
bilirubin
median
vs
remain
unchang
except
obviou
increment
patient
fig
increas
vs
measur
constantli
perform
patient
trial
found
could
indicaterecov
lung
functionthi
tempor
relationship
notabl
despit
provis
maxim
support
care
antivir
agent
remark
patient
male
admit
dpoi
quick
recoveri
much
improv
result
laboratori
test
receiv
antivir
drug
arbidol
ribavirin
treatment
high
flow
nasal
cannula
admiss
mechan
ventil
given
dpoi
critic
care
support
cp
transfus
perform
dpoi
dpoi
turn
neg
sharp
decreas
crp
mgl
mgl
incrementof
fig
mechan
ventil
success
wean
day
cp
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
transfus
dpoi
steadi
elev
oflymphocyt
count
drop
ofaminopheras
levelwer
observ
indic
improv
ofimmunolog
hepat
function
determin
neutral
antibodi
titer
cp
transfus
patient
except
one
tabl
neutral
antibodi
titer
five
patient
increas
four
patient
remain
atth
level
cp
rna
assay
revers
transcriptasepolymeras
chain
reaction
rtpcr
posit
seven
patient
neg
three
case
cp
transfus
note
rna
decreas
anundetect
level
patient
day
patient
day
patient
day
cp
therapythes
result
support
anneutr
effectof
cp
serum
control
group
form
random
select
patient
cohort
treat
hospit
andmatch
age
gender
sever
diseas
case
trial
baselin
characterist
patient
cp
treatment
group
control
group
show
signific
differ
clinic
outcomesof
two
group
werediffer
case
dischargedwhil
case
much
improv
statu
readi
discharg
cp
group
compar
death
case
stabliz
statu
one
case
improv
control
group
p
supplementari
tabl
patient
show
evanesc
facial
red
spot
seriou
advers
reaction
safeti
event
record
cp
transfus
knowledg
first
studi
explor
feasibl
cp
therapi
enrol
sever
patient
achiev
primari
secondari
outcom
one
dose
ml
cp
transfus
welltoler
clinic
symptom
significantli
improv
increas
oxyhemoglobin
satur
within
day
accompani
rapid
neutral
viremia
sever
pneumonia
caus
human
coronaviru
character
rapid
viral
replic
massiv
inflammatori
cell
infiltr
elev
proinflammatori
cytokin
even
cytokin
storm
alveoli
lung
result
acut
pulmonari
injuri
acut
respiratori
distress
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
syndrom
ard
recent
studi
demonstr
lymphocyt
count
peripher
blood
remark
decreas
level
cytokin
plasma
patient
requir
icu
support
includ
gmcsf
significantli
higher
requir
icu
condit
cp
obtain
recov
patient
establish
humor
immun
viru
contain
larg
quantiti
neutral
antibodi
capabl
neutral
erad
pathogen
blood
circul
pulmonari
tissu
present
studi
investig
patient
achiev
serum
rna
neg
cp
transfus
accompani
increas
oxygen
satur
lymphocyt
count
improv
liver
function
creactiv
protein
result
suggest
inflamm
overreact
immun
system
allevi
antibodi
contain
cp
casefat
rate
cfr
present
studi
compar
cfr
sar
vari
four
noncompar
studi
use
cp
treatment
base
preliminari
result
cp
therapi
easyaccess
promis
safe
rescu
option
sever
patient
nevertheless
worth
mention
absorpt
pulmonari
lesion
often
behind
improv
clinic
symptom
shown
patient
trial
first
key
factor
associ
cp
therapi
neutral
antibodi
titer
small
sampl
studi
merscov
infect
show
neutral
antibodi
titer
exceed
achiev
effect
cp
therapi
find
elig
donor
high
level
neutral
antibodi
prerequisit
cao
et
al
show
level
specif
neutral
antibodi
sarscov
decreas
gradual
month
diseas
process
reach
undetect
level
igg
neutral
antibodi
patient
month
diseas
statu
studi
merscov
infect
patient
expos
healthcar
worker
show
preval
merscoviggseroreact
low
antibodi
titer
decreas
rapidli
within
month
studi
suggest
neutral
antibodi
repres
shortlast
humor
immun
respons
plasma
recent
recov
patient
effect
present
studi
recent
recov
patient
infect
neutral
antibodi
titer
recruit
local
hospit
consid
suitabl
donor
median
age
donor
lower
recipi
vs
year
among
nine
case
investig
neutral
antibodi
titer
five
patient
increas
four
patient
kept
level
within
two
day
antibodi
titer
cp
seem
thu
higher
use
treatment
mer
patient
second
key
factor
associ
efficaci
treatment
time
point
better
treatment
outcom
observ
among
sar
patient
given
cp
dpoi
vs
p
highlight
import
time
rescu
therapi
mean
time
onset
ill
cp
transfus
day
consist
previou
research
three
patient
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
receiv
plasma
transfus
given
dpoi
patient
studi
show
rapid
increas
lymphocyt
count
decreas
crp
remark
absorpt
lung
lesion
ct
notabl
patient
receiv
cp
transfus
dpoi
show
much
less
signific
improv
patient
howev
dynam
viremia
unclear
optim
transfus
time
point
need
determin
futur
present
studi
sever
advers
effect
observ
one
risk
plasma
transfus
transmiss
potenti
pathogen
methylen
blue
photochemistri
appli
studi
inactiv
potenti
residu
viru
maintain
activ
neutral
antibodi
much
possibl
method
known
much
better
ultraviolet
c
light
specif
viru
detect
transfus
transfusionrel
acut
lung
injuri
trali
report
ebola
viru
diseas
woman
receiv
cp
therapi
although
uncommon
gener
popul
receiv
plasma
transfus
specif
advers
reaction
worth
note
especi
among
critic
ill
patient
experienc
signific
pulmonari
injuri
anoth
rare
risk
worth
mention
cp
therapi
antibodydepend
infect
enhanc
occur
subneutr
concentr
could
suppress
innat
antivir
system
thu
could
allow
logarithm
intracellular
growth
viru
special
immun
enhanc
reportedli
common
dengu
fever
also
could
found
sar
patient
probabl
owe
high
level
neutral
antibodi
time
transfus
appropri
plasma
volum
limit
present
studi
first
except
cp
transfus
patient
receiv
standard
care
patient
receiv
antivir
treatment
despit
uncertainti
efficaci
drug
use
result
possibl
thatthes
antivir
agent
could
contribut
recoveri
patient
synerg
therapeut
effect
cp
could
rule
furthermor
patient
receiv
glucocorticoid
therapi
might
interfer
immun
respons
delay
viru
clearanc
second
median
time
onset
symptom
cp
transfus
day
day
although
kinet
viremia
natur
histori
remain
unclear
relationship
rna
reduct
cp
therapi
well
asth
optim
concentr
neutral
antibodi
treatment
schedul
clarifi
third
dynam
chang
cytokin
treatment
investig
nevertheless
preliminari
result
trial
seem
promis
justifi
random
control
clinic
trial
larger
patient
cohort
conclus
pilot
studi
cp
therapi
show
potenti
therapeut
effect
low
risk
treatment
sever
patient
one
dose
cp
high
concentr
neutral
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
antibodi
rapidli
reduc
viral
load
tend
improv
clinic
outcom
optim
dose
treatment
time
point
well
definit
clinic
benefit
cp
therapi
need
investig
random
clinic
studi
respiratori
distress
rr
beatsmin
oxygen
satur
level
less
rest
state
partial
pressur
oxygen
oxygen
concentr
mmhg
kpa
exclus
criteria
follow
previou
allerg
histori
plasma
ingredi
sodium
citrat
case
seriou
gener
condit
sever
organ
donor
depend
age
bodi
weight
sampl
divid
store
ml
aliquot
without
deterg
heat
treatment
cp
treat
methylen
blue
light
treatment
minut
medic
plasma
viru
inactiv
cabinet
shandong
zhongbaokang
medic
applianc
co
ltd
neutral
activ
plasma
determin
plaqu
reduct
neutral
test
use
patient
admit
intens
care
unit
icu
receiv
antivir
therapi
support
care
somepati
receiv
antibiot
treatment
antifung
treatment
glucocorticoid
oxygen
support
appropri
situat
one
dose
ml
inactiv
cp
neutral
activ
transfus
patient
within
hour
follow
blood
transfus
protocol
clinic
symptom
record
attend
physician
daili
blood
test
biochem
test
carri
everi
day
rna
detect
everi
day
ct
scan
repeat
everi
day
primari
endpoint
safeti
cp
transfus
second
endpoint
improv
clinic
symptom
laboratori
radiolog
paramet
within
day
cp
transfus
clinic
symptom
improv
defin
temperatur
normal
relief
dyspnea
oxygen
satur
normal
radiolog
improv
defin
differ
degre
absorpt
lung
lesion
continu
variabl
present
median
interquartil
rang
iqr
graph
plot
use
graphpad
prism
statist
softwar
use
includ
spss
data
support
find
studi
avail
correspond
author
reason
request
particip
data
without
name
identifi
made
avail
approv
correspond
author
public
studi
find
data
avail
other
request
research
team
provid
email
address
commun
data
approv
share
other
propos
detail
descript
studi
object
statist
analysi
plan
need
evalu
reason
request
data
correspond
author
make
decis
base
materi
addit
materi
may
also
requir
process
tbiltot
bilirubin
altalanin
aminotransferas
astaspart
aminotransferas
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
